US Patent 8613949 | US Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
NEW Find Prospects
- Prospector
Drugs in Dev.
News
Blog
Market Place
Login

Novartis Pharmaceuticals Corporation

Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

Contact Supplier

Evonik Health Care is the innovation hub for leading life science companies

Contact Supplier

Aarti Pharmalabs is a partner of choice for pharmaceutical companies for APIs & Intermediates. Largest Indian producer of Caffeine.

Contact Supplier

Axplora is your partner of choice for complex APIs.

Contact Supplier

Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

Contact Supplier

pharmacompass-2-2026-02-09

Novartis Pharmaceuticals Corporation

VIRTUAL BOOTH, Contact Details

VIRTUAL BOOTH
CONTACT DETAILS
Google Map, LinkedIn, Emails...

EVENTS

Webinars & Exhibitions

Webinars & Exhibitions

DIGITAL CONTENT

Interview #SpeakPharma, Vlog #PharmaReel, Data Compilation #PharmaFlow, 5073 News #PharmaBuzz

Interview #SpeakPharma
Vlog #PharmaReel
Data Compilation #PharmaFlow
5073 News #PharmaBuzz

ACTIVE PHARMA INGREDIENTS

237 All APIs, 45 USDMF, 98 CEP/COS, 2 JDMF, 31 KDMF, 112 NDC API, 1 VMF, 1 Listed APIs

237 All APIs
45 USDMF
98 CEP/COS
2 JDMF
31 KDMF
112 NDC API
1 VMF
1 Listed APIs

DEVELOPMENTS

2925 Drugs in Development

2925 Drugs in Development

FINISHED DOSAGE FORMULATIONS

3139 FDF Dossiers, 373 FDA Orange Book, 2014 Europe, 170 Canada, 579 Australia, 3 Listed Dossiers

3139 FDF Dossiers
373 FDA Orange Book
2014 Europe
170 Canada
579 Australia
3 Listed Dossiers

EXCIPIENTS

3 All Excipients, 3 USDMF

3 All Excipients
3 USDMF

REF. STANDARDS & IMPURITIES

1 Others

1 Others

INSPECTIONS & REGISTRATIONS

144 FDA, 1 EDQM, 2 GDUFA

144 FDA
1 EDQM
2 GDUFA

Xls

Filters

Reset all filters

Filters

FILTER :

filter Applicant Reset all filters

4 All

01 4NOVARTIS

filter Patent Number Reset all filters

4 All

01 48613949

API Patent Reset all filters

4 All

01 4Blank

filter FDF Patent Reset all filters

4 All

01 4Y

filter Expiration Date Reset all filters

4 All

01 42029-12-21

01

NOVARTIS

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE

BioProcess International US West

Not Confirmed

NOVARTIS

BioProcess International US West

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2029-12-21

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE

US Patent Number : 8613949

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 22545

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2029-12-21

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

NOVARTIS

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE

BPI West

Not Confirmed

NOVARTIS

BPI West

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2029-12-21

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE

US Patent Number : 8613949

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 22545

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2029-12-21

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

NOVARTIS

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE

BPI West

Not Confirmed

NOVARTIS

BPI West

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2029-12-21

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE

US Patent Number : 8613949

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 22545

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2029-12-21

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

04

NOVARTIS

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE

BPI West

Not Confirmed

NOVARTIS

BPI West

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2029-12-21

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE

US Patent Number : 8613949

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 22545

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2029-12-21

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.